Atypical neuroleptic malignant syndrome: Diagnostic controversies and considerations

Pharmacotherapy

Volumn 28, Issue 4, 2008, Pages 530-535

  Picard, Lara S ^a   Lindsay, Shane ^a   Strawn, Jeffrey R ^b   Kaneria, Rakesh M ^b   Patel, Nick C ^c,d   Keck Jr , Paul E ^b,e  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e LINDNER CENTER OF HOPE   (United States)

Author keywords

Antipsychotics; Dopamine; Neuroleptic malignant syndrome; Neuroleptics; NMS

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DOPAMINE; OLANZAPINE; RISPERIDONE;

ATYPICAL NEUROLEPTIC MALIGNANT SYNDROME; EXTRAPYRAMIDAL SYNDROME; HYPERTHERMIA; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTRANSMITTER RELEASE; PATHOGENESIS; PATHOPHYSIOLOGY; SHORT SURVEY;

ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEVER; HUMANS; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 41549141349     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.4.530     Document Type: Short Survey

References (34)

1. Keck PE Jr, Pope HG Jr, Cohen BM, McElroy SL, Nierenberg AA. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 1989;46:914-18.
2. Nisijima K, Ishiguro T. Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. Biol Psychiatry 1990;27:280-8.
3. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-6.
4. Caroff SN. Neuroleptic malignant syndrome: still a risk, but which patients may be in danger? Curr Psychiatry 2003;2:36-42.
5. Rosenberg MR, Green M. Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 1989;149:1927-31.
6. Davis JM, Caroff SN, Mann SC. Treatment of neuroleptic malignant syndrome. Psychiatr Ann 2000;30:325-31.
7. Amore M, Zazzeri N, Berardi D. Atypical neuroleptic malignant syndrome associated with clozapine treatment. Neuropsychobiology 1997;35:197-9.
8. Newman M, Adityanjee, Jampala C. Atypical neuroleptic malignant syndrome associated with risperidone treatment [letter]. Am J Psychiatry 1997;154:1475.
9. Reeves RR, Torres RA, Liberto V, Hart RH. Atypical neuroleptic malignant syndrome associated with olanzapine. Pharmacotherapy 2002;22:641-4.
10. Spalding S, Alessi NE, Radwan K. Aripiprazole and atypical neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 2004;43:1457-8.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, text revision, 4th ed. Washington, DC: American Psychiatric Association, 2000.
12. Caroff SN, Mann SC, Lazarus A, Sullivan KL, Macfadden W. Neuroleptic malignant syndrome: diagnostic issues. Psychiatr Ann 1991;21:130-47.
13. Pope HG, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry 1986;143:1227-33.
14. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive patients. Am J Psychiatry 1986;143:1587-90.
15. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137-45.
16. Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res 2005;135:249-56.
17. Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980;41:79-83.
18. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155:1113-16.
19. Scelsa SN, Simpson DM, McQuistion HL, Fineman A, Ault K, Reichler B. Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology 1996;47:1518-23.
20. Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 1992;31:1161-4.
21. Caroff SN, Mann SC, Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann 2000;30:314-21.
22. Farver DK. Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2003;2:21-35.
23. Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand 2005;112:238-40.
24. Strawn JR. Aripiprazole and the neuroleptic malignant syndrome. Schizophr Res 2006;85:298-9.
25. Karagianis JL, Phillips LC, Hogan KP, LeDrew KK. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 1999;33:623-30.
26. Mann SC, Caroff SN, Fricchione G, Campbell EC. Central dopamine hypoactivity and the pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann 2000;30:363-74.
27. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77;185-202.
28. Thornberg SA, Ereshefsky L. Neuroleptic malignant syndrome associated with clozapine monotherapy. Pharmacotherapy 1993;13:510-14.
29. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;156:169-80.
30. Spivak B, Maline DI, Vered Y, et al. Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignant syndrome. Acta Psychiatr Scand 2000;102:226-30.
31. Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res 1995;29:233-44.
32. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000;61(suppl 3):16-21.
33. Troller JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999;33:650-9.
34. Reulbach U, Dutsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007;11:R4. Available from http://dx.doi.org/10.1186/cc5148.